We are live on
!
Find out more
FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$237M
1-Year Est. Return
107.53%
This Fund
S&P 500
This Quarter
Est. Return
-19.06%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$81.1M
AUM Growth
-$151M
(-65%)
Cap. Flow
-$120M
Cap. Flow
% of AUM
-147.31%
Top 10 Holdings %
Top 10 Hldgs %
98.88%
Holding
18
New
4
Increased
2
Reduced
5
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$7.15M |
| 2 |
BLUE
bluebird bio
BLUE
|
+$3.76M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$3.01M |
| 4 |
uniQure
QURE
|
+$1.1M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
+$1.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDCO
Medicines Co
MDCO
|
+$34.2M |
| 2 |
AERI
Aerie Pharmaceuticals
AERI
|
+$24.2M |
| 3 |
Insmed
INSM
|
+$17.8M |
| 4 |
Arbutus Biopharma
ABUS
|
+$10.3M |
| 5 |
Ascendis Pharma A/S
ASND
|
+$9.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cytokinetics
CYTK
$10.6B
| $25.7M | 31.64% |
2,177,292
-221,678
| -9% | -$2.83M |
|
|
MYOK
2
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $14.4M | 17.76% |
307,400
+47,030
| +18% | +$3.01M |
|
3
Fulcrum Therapeutics
FULC
$241M
| $11.9M | 14.7% |
998,655
-501,345
| -33% | -$8.02M |
|
|
4
Insmed
INSM
$22.4B
| $10.9M | 13.4% |
678,322
-751,196
| -53% | -$17.8M |
|
|
BHVN
5
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $5.32M | 6.56% |
+156,355
| New | +$7.15M |
|
6
Voyager Therapeutics
VYGR
$181M
| $4.73M | 5.83% |
516,751
-313,814
| -38% | -$3.6M |
|
|
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
| $3.07M | 3.79% |
227,717
-1,273,683
| -85% | -$24.2M |
|
|
BLUE
8
DELISTED
bluebird bio
BLUE
| $2.3M | 2.83% |
+3,860
| New | +$3.76M |
|
|
9
Kiniksa Pharmaceuticals
KNSA
$6.23B
| $1.01M | 1.24% |
+65,000
| New | +$1.02M |
|
10
Kura Oncology
KURA
$793M
| $925K | 1.14% |
93,000
+25,000
| +37% | +$286K |
|
|
11
uniQure
QURE
$2.75B
| $905K | 1.12% |
+19,082
| New | +$1.1M |
|
|
12
Arbutus Biopharma
ABUS
$847M
| – | – |
-3,705,128
| Closed | -$10.3M |
|
13
Alector
ALEC
$169M
| – | – |
-353,462
| Closed | -$6.09M |
|
|
14
Ascendis Pharma A/S
ASND
$16.5B
| – | – |
-68,981
| Closed | -$9.6M |
|
|
OPTN
15
DELISTED
OptiNose
OPTN
| – | – |
-58,051
| Closed | -$8.03M |
|
16
SI-BONE Inc
SIBN
$818M
| – | – |
-308,183
| Closed | -$6.63M |
|
|
CBAY
17
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-2,315,016
| Closed | -$4.54M |
|
|
MDCO
18
DELISTED
Medicines Co
MDCO
| – | – |
-403,217
| Closed | -$34.2M |
|
Similar funds
BCM
ICMM
AG
FL
EA
PVM
MFA
TCM
Foresite Capital Management IV's Q1 2020 Portfolio in Review
As of Q1 2020, Foresite Capital Management IV held 18 positions worth $81.1M, down 65% from $232M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Foresite Capital Management IV withdrew a net $120M in Q1 2020, closing 7 positions and reducing 5 holdings. Its most notable exit was Medicines Co, an estimated $34.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 70% a quarter earlier.
Against the trend, Foresite Capital Management IV opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $5.32M.
- Foresite Capital Management IV's largest Q1 2020 buy was Biohaven Pharmaceutical Holding Company Ltd.: 156,355 shares worth $5.32M.
- Foresite Capital Management IV added most to MyoKardia, Inc. Common Stock in Q1 2020, an estimated $3.01M increase.
- Foresite Capital Management IV's biggest Q1 2020 reduction was Aerie Pharmaceuticals, cutting an estimated $24.2M.
- Foresite Capital Management IV fully exited Medicines Co in Q1 2020, selling an estimated $34.2M.
- Foresite Capital Management IV's ten largest holdings make up 99% of its $81.1M portfolio in Q1 2020.
- Foresite Capital Management IV opened 4 new positions and closed 7 in Q1 2020.
- Foresite Capital Management IV's portfolio value fell 65% quarter-over-quarter to $81.1M.
Based on Foresite Capital Management IV's 13F filing for Q1 2020, filed 14 May 2020.